InterVenn Biosciences Announces the Publication of Early Detection of Advanced Adenoma and Colorectal Cancer in Gastroenterology, the Flagship Journal of the American Gastroenterological Association
InterVenn Biosciences , a life sciences company pioneering glycoproteomics, today announced the publication of their discovery work in Advanced Adenoma (AA) and Colorectal Cancer (CRC) early disease detection in the flagship journal of the American Gastroenterological Association, Gastroenterology.
- InterVenn Biosciences , a life sciences company pioneering glycoproteomics, today announced the publication of their discovery work in Advanced Adenoma (AA) and Colorectal Cancer (CRC) early disease detection in the flagship journal of the American Gastroenterological Association, Gastroenterology.
- This groundbreaking research in early detection of CRC represents an advancement in early diagnosis through serum glycoproteome profiling.
- The results published in Gastroenterology establish the groundwork for a blood-based CRC screening modality using artificial intelligence to reveal the earliest stages of colorectal cancer.
- Desai K, Gupta S, May FP, Xu G, Shaukat A, Hommes DW, NICE-AA/CRC- Consortium, Early detection of advanced adenomas and colorectal carcinoma by serum glycoproteome profiling., Gastroenterology (2023), doi: https://doi.org/10.1053/j.gastro.2023.09.034